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Introduction 
Inflammatory response is one of the phylogenetically
oldest responses of the body, which serves the purpose of
defending the organism against intruding micro-organisms.
Thus, it is a host-defence response, elicited to maintain the
integrity of the host. If successful, transient inflammatory
response resolves and results in a safe elimination of the
micro-organism. However, similarly to some other
biological responses, inflammatory response bears a
potential of tissue injury. If this tightly regulated
inflammatory reaction escapes the control of the host, it may
end up with acute reactions, such as hypersensitivity, septic
shock or with chronic inflammation, such as rheumatoid
arthritis or atherosclerosis. The excessive inflammatory
response leads to host tissue injury and may be fatal. 
Mediators, which govern the recruitment of
inflammatory cells and the intensity of the inflammatory
response, include free radicals (such as NO
.
, O2
–), lipid
mediators (such as derivatives of arachidonic acid -
prostaglandins and leukotrienes), cytokines (such as IL-1,
IFN-γ, TNF-α) or protein cascades (such as kinin and
complement systems). 
Nitric oxide (NO) may represent a good example of a
mediator of inflammation, which – as the entire
inflammatory response - is either protective or detrimental
to the host. Here, we briefly review biology and
biochemistry of NO, and attempt to explain how a single
mediator of inflammation, such as NO, may protect the host,
kill micro-organisms on one hand, and contribute to the
tissue injury of the host on the other. 
Biology of NO 
Nitric oxide (NO) is a free radical derived from L-
arginine through the action of isoforms of nitric oxide
synthase. Two of these isoforms are expressed constitutively,
i.e. endothelial - eNOS (NOS-3) and neuronal - nNOS
(NOS-1) and their activity is crucially dependent on
intracellular calcium ions. The third isoform, an inducible
one - iNOS (NOS-2) - is a calcium-independent enzyme
triggered by proinflammatory stimuli such as endotoxin or
cytokines (IL-1, IFN-γ, TNF-α). In biological systems, NO
is a short-living molecule with a half-life of about 6 seconds,
as it instantly interacts with other free radicals, biological
targets or is transformed to nitrite and nitrate [1]. 
When the production of NO is triggered by physiological
stimuli, it evokes its biological effects in cardiovascular and
nervous systems mainly by activation of guanylate cyclase,
with subsequent elevation of intracellular cGMP [2]. This
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second messenger, activated by endogenous or exogenous
NO, leads, for example, to relaxation of vascular smooth
muscles, inhibition of leukocyte or platelet
adhesion/activation, inhibition of chemotaxis of monocytes,
as well as to inhibition of proliferation of vascular smooth
muscle cells. Noteworthy, some NO-mediated responses were
claimed to be cGMP-independent [3]. 
NO produced by inducible NOS in higher concentrations
than those produced by constitutive NOS isoforms, plays a
role in host defence against various pathogens [4]. Toxic
antimicrobial and antitumor [5] effects of NO derived from
NOS-2 were initially attributed to the direct effect of NO on
DNA or other vital macromolecules. At present, it is rather
accepted that toxic effects of NO are related to the products
of reactions of NO with other free radicals. 
Biochemistry of NO
NO is a highly reactive molecule which interacts with
oxygen, transition metals, and reactive oxygen species (ROS),
especially with superoxide anion [6]. The interaction of NO
and O2
– results in a formation of peroxynitrite ONOO–, that
can further decompose into highly toxic products, such as,
e.g., hydroxyl radical (OH) [7] or in the presence of thiols it
may be transformed to nitrate or S-nitrosothiols [8]. Toxic
effects of ONOO– are related to nitration of tyrosine residues
of various functional or structural proteins leading to their
irreversible alterations or to irreversible inhibition of
mitochondrial respiratory chain [9]. On the other hand, it is
currently discussed whether the nitration of proteins is
involved in physiological cell signalling [10].
In the cardiovascular system there are numerous
enzymatic sources of O2
–, which could be involved in the
formation of ONOO-. These include NADPH oxidase of
activated neutrophils, platelets, as well as various enzymes
in vessel wall, such as vascular NADPH oxidase, xanthine
oxidase or others [11]. Biological activity of O2
- produced
by these enzymes is under control of numerous antioxidant
systems such as intra- and extra-cellular SOD as well as
catalase, gluthatione proxidase or others [11]. 
Noteworthy, evidence accumulated suggesting that
redox forms of NO, i.e. nitrosonium ion (NO+) or nitroxyl
anion (NO–), generally described as reactive nitrogen oxide
species (RNOS), are much more reactive then NO itself
[12]. RNOS avidly react with intracellular and extracellular
thiols (glutathione, cysteine residues, albumine). These
reactions seem to play an important role in cell signalling
as well as in transport of NO in the circulation. Indeed,
nitrosonium ion-dependent regulation of gene expression
was recently claimed [13], and S-nitroso-albumin was
suggested to constitute the reservoir of NO in the circulation
[14, 15]. In summary, it is becoming apparent that both
biological and toxic effects of NO involve much wider
scope of reactions and targets than those related to NO-
dependent activation of guanylate cyclase.
NO in chronic inflammation 
It is well known that expression of NOS-2 is increased
in various inflammatory diseases, such as atherosclerosis,
chronic heart disease, host vs. graft disease, rheumatoid
arthritis, as well as in numerous neurodegenerative diseases
[16]. In all these diseases increased formation of NO was
reported as assessed by levels of nitrites and nitrates in
plasma, by molecular biology methods as well as by other
assays, not always relevant. For example, free 3-nitrotyrosine
was found in the serum and synovial fluid of patients
suffering of rheumatoid arthritis, and this finding was
considered as a marker of increased formation of NO [17].
However, formation of 3-nitrotyrosine results from biological
action of secondary reactive nitrogen oxide species (ONOO–)
rather than from NO itself. Moreover, human neutrophils are
able to nitrate tyrosine, using nitrite as a substrate and
myeloperoxidase - the same enzyme that takes part in the
process of chlorination of proteins [18]. Accordingly, a level
of 3-nitrotyrosine does not reflect NO production, but it may
rather mirror the intensity of inflammation. 
The major impact of NO on the host in chronic
inflammation is related to the fact that it can contribute to
the organ injury. In particular, NO is claimed to contribute
to damage of the joint cartilage in rheumatoid arthritis, to
mucosal injury in inflammatory bowel disease and to
degeneration of neurons in neurodegenerative diseases, such
as Parkinson’s, Huntington’s and Alzheimer’s diseases [16].
A deleterious action of NO in neurodegenerative
diseases is further supported by the use of knockout mice
lacking NOS-2. These mice were resistant to the
experimentally induced toxicity in central nervous system
[16]. Also, NOS-2 inhibitors used in some experimental
animal models of chronic inflammatory diseases were able
to alleviate the symptoms of inflammation and diminish
injury of the inflamed tissue [19].
NO in septic shock
Septic shock and its complications such as ARDS or
multiple organ injury represent the extreme clinical outcome
of the inflammatory response. Extensive work have been
undertaken to clarify the role of NO in this serious disease.
Below we present the short overview on the involvement of
NO in systemic inflammatory response induced by bacterial
endotoxin with particular emphasis on the detrimental and
beneficial side of NO action in systemic inflammation. 
It is known since a decade that hypotension and
vasoplegia (refractoriness to vasoconstrictor agents) in
endotoxic shock are mediated by NO produced by NOS-2
induced in vascular wall by LPS or inflammatory cytokines.
Indeed, inhibition of NOS-2 in endotoxaemia or septic
shock reversed hypotension, and restored vascular
responsiveness to vasoconstrictor agents [20]. More recently
it was shown that NOS-2 derived NO contributes also to
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organ injury in endotoxic shock. In fact, numerous reports
demonstrated organ-protective effects of NOS inhibition as
they limited lung, liver, kidney or intestine injury [21-24]
in endotoxic shock. Similarly to other inflammatory
conditions described above, toxic effect of NO was initially
attributed to the direct detrimental action of high nanomolar
concentration of NO on mitochondrial respiration and DNA
structure. Then it was suggested to be rather of indirect
nature related to the formation of ONOO-. Indeed,
endotoxin-induced organ injury was also reduced by SOD
mimetics and peroxynitrite decomposition catalyst [24] 
Importantly, the belief of the important contribution of
NOS-2 derived NO to the pathophysiology of septic shock
led to large clinical trials with NOS inhibitors. Their results,
however, were disappointing and were prematurely withheld
due to the increased trend in mortality of patients treated
with L-NMMA, a non-selective NOS inhibitor [25]. 
Not only in clinical trials but also in the majority of the
animal studies non-selective inhibitors, such as L-NAME or
L-NMMA, were used in order to inhibit NOS-2, [20, 26].
These agents along with the inhibition of NOS-2 limited at the
same time the activity of NOS-3 in endothelium. This is why,
after L-NAME-treatment of animals with endotoxic shock,
excessive vasoconstriction appeared resulting in subnormal
organ perfusion [27], as well as in depression of cardiac output
[28], aggravation of liver [29], intestine [30] and lung [31, 32]
injury. Clearly, NOS inhibition was not always beneficial, and
could be detrimental, leading to the increased mortality rate in
endotoxic shock or septic shock [25]. 
The mechanisms of the protective action of NO
generated by NOS-3 in host response to LPS could result
from its vasodilator [27], antiplatelet [33] or antileukocyte
[34] activities. In studies carried out in the Department of
Pharmacology in Krakow, it was shown that NO produced
by pulmonary endothelium was a life-saving mediator of
endotoxaemic animals by its capability to safeguard
pulmonary microcirculation. We have proposed that it is
related to the fact that the removal of bacterial LPS from
circulation takes place in pulmonary microcirculation and
it involves activation and intercelullar interactions of
sequestrated neutrophils and platelets. If this multicellular
event mediated by complement-dependent activation of
platelets and neutrophils is not tempered by endogenous
NO, it is associated with the acute microvascular lung injury
and fatal pulmonary oedema [35]. 
Beneficial effects of NO in endotoxaemia described
above depended clearly on NOS-3. However, the growing
evidence indicates that NO produced by NOS-2 may also
be cytoprotective [36] not only in endotoxic shock but also
in other inflammatory diseases as well. In fact, it was
recently shown, that selective inhibition of NOS-2
exacerbated the damage of inflamed joint [37]. 
What mechanisms could be involved in the anti-
inflammatory action of NO derived from NOS-3 or NOS-
2? Inhibitory action of NO on platelets and leukocytes is
clearly anti-inflammatory, as these cells ignite the
inflammation. NO can act as an anti-inflammatory molecule
also by its ability to inhibit NF-κB activation, the major pro-
inflammatory transcription factor [38]. Indeed, NF-κB is
involved in inflammatory response of endothelium as it
activates the expression of various adhesion molecules (e.g.
ICAM, selectin E) and pro-inflammatory cytokines such as
IL-6 or IL-8 [39]. Accordingly, one may expect that the
major biological role of NO produced by vessel wall,
irrespectively of whether by NOS-3 or NOS-2, is to prevent
the endothelium from assuming the inflammatory phenotype
[40]. Still, the general view is that NOS-2 derived NO is a
pro-inflammatory, not anti-inflammatory mediator. 
NO regulation in immune system
The literature on the contribution of NO to organ injury
in acute or chronic inflammation often neglects the role of
NO in direct regulation of mechanisms of innate and
acquired immunity. Obviously, induction of NOS-2 in
inflammation is regulated by pro-inflammatory cytokines
of innate response. On the other hand, there is evidence
indicating that endogenous NO released at a site of
inflammation by phagocytic cells or from vessel wall may
contribute to cross-talk between inflammatory cells (innate
immunity) and Th1/Th2 cells (acquired immunity) and even
to fine tuning of Th1/Th2 immune response.
Indeed, it is commonly accepted that Th1 type cytokines,
especially IFN-γ, induce the expression of NOS-2 and enhance
the synthesis of NO. Conversely, the production of NO can
be inhibited by Th2 type cytokines, such as IL-4 and IL-10.
This may occur at two levels. First, it can be blocked directly,
as these cytokines inhibit NOS-2 transcription in target cells.
Second, it can be inhibited indirectly, since IL-4 and IL-10
diminish production of IFN-γ by inflammatory cells. 
On the other hand, exogenous NO regulates in vitro
cytokine production by T cells, though the profile of its
activity is still not clear. It is generally accepted that NO at
a high concentration is immune-suppressive. Indeed, some
authors [41] show indiscriminative inhibition of production
of Th1 and Th2 type of cytokines (IL-2, IL-4, IL-5, IL-10
and IFN-γ) by NO-donors. Others suggest that NO donors
inhibit production of Th1 type cytokines (IFN-γ, IL-2), but
not those of Th2 type (IL-4, IL-10) [42]. 
To complicate the matters further, recently it was
demonstrated that low concentrations of NO selectively
enhance the differentiation of Th1, but not Th2 cells. The
authors show that NO, in a cGMP-dependent way, induced
the expression of IL-12 receptor, a key cytokine in induction
of Th1 differentiation [43]. 
In spite of these controversies, which may result from
the different experimental systems, the contribution of NO
to regulation of cytokine generation seems to be
documented. Yet, many questions are left unsolved. 
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In summary, NO displays multiple actions in
inflammatory response. Importantly, it protects the host and
contributes to the tissue injury of the host. The classical
view that protective vs. detrimental nature of NO depends
on the source of its production (NOS-3 vs. NOS-2) seems
to be no longer tenable. The detrimental role of NO may be
rather explained by the formation of secondary products of
NO in oxidant stress environment. Accordingly, the
pharmacotherapy of inflammatory diseases should perhaps
aim at the restoration of NO protective properties and at the
inhibition of deleterious effects of reactive species of oxygen
and nitrogen. Whether this approach will bring beneficial
modulation of Th1/Th2 balance remains to be determined. 
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